Your Article Summary
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
Chugai Pharmaceutical Co., 07/01/09
Chugai Pharmaceutical Co., Ltd. announced that Phase III study of the recombinant human erythropoietin "Epogin Injection" achieved the primary endpoint by significantly reducing the theoretical transfusion rate in patients with chemotherapy induced anemia.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Randomized Trial of Doxycycline for Mansonella perstans Infection
New England Journal of Medicine, 10/08/09
Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
Clinical Cancer Research, 10/19/09
Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention
Trials, 10/28/09
Article Search
Sponsor


See Latest Articles


